International Journal of Myeloma 8巻 2号

発行元
日本骨髄腫学会
ISSN
ISSN(オンライン)
2187-3143
旧名・別名
抄録集:日本骨髄腫研究会総会 プログラム・抄録集

書籍情報から探す
開始頁
第43回 日本骨髄腫学会学術集会 ご挨拶
中世古知昭
第43回日本骨髄腫学会学術集会 会長, 国際医療福祉大学医学部 血液内科
International Journal of Myeloma 8 (2) 3-3, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL. Molecular analysis of pathophysiology and development of treatment starategy for the cure of POEMS syndrome
Chiaki Nakaseko
Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 48-48, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
IL. Discovery of cereblon as a primary target of thalidomide and therapeutic applications of cereblon modulators
Hiroshi Handa, Takumi Ito
Department of Nanoparticle Translational Research, Tokyo Medical University
International Journal of Myeloma 8 (2) 49-49, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
JSY-1. Clinical studies on multiple myeloma in Japan
Shuji Ozaki
Department of Hematology Tokushima Prefectural Central Hospital
International Journal of Myeloma 8 (2) 52-52, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
JSY-2. Epigenetic regulation of drug resistance in multiple myeloma
Yusuke Furukawa, Yoshiaki Kuroda, Jiro Kikuchi
Division of Stem Cell Regulation, Jichi Medical University
International Journal of Myeloma 8 (2) 53-53, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
JSY-3. Epidemiology of Multiple Myeloma in South Korea
Jae Hoon Lee
Division of Hematology, Gachon University Gil Medical Center Incheon
International Journal of Myeloma 8 (2) 54-54, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
JSY-4. Clinical Study for Multiple Myeloma in Korea : Experience of The Korean Multiple Myeloma Working Party
Jin Seok Kim1, Je-Jung Lee2, Kihyun Kim3, Jae Hoon Lee4, Sung-Soo Yoon5, Hyo Jung Kim6, Dong-Yeop Shin5, Chang-Ki Min7
1Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, 2Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 3Department of Medicine, Samsung Medical Center, 4Department of Internal Medicine, Gachon University Gil Hospital, 5Department of Internal Medicine, Seoul National University Hospital, 6Department of Internal Medicine, Hallym University Sacred Heart Hospital, 7Department of Internal Medicine, Seoul St.Mary's Hospital, Catholic University of Korea
International Journal of Myeloma 8 (2) 55-55, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-1. Mechanism of multiple myeloma development by BM microenvironment and choice of intervention
Yoshiaki Kuroda1, Jiro Kikuchi1, Daisuke Koyama1, Tatsuo Ichinohe2, Yusuke Furukawa1
1Division of Stem Cell Regulation Center for Molecular Medicine, Jichi Medical University, 2Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
International Journal of Myeloma 8 (2) 58-58, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-2. Molecular biology of multiple myeloma : mechanism of action and resistance to the therapeutic agents
Masaki Ri
Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences.
International Journal of Myeloma 8 (2) 59-59, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-4. Aberrant epigenetics of multiple myeloma
Hiroshi Handa
Department of Hematology, Gunma University Hospital
International Journal of Myeloma 8 (2) 61-61, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-1. Prognostic value of minimal residual disease detection in patients with multiple myeloma : Recent topics
Hiroyuki Takamatsu
Hematology / Respiratory Medicine, Kanazawa University
International Journal of Myeloma 8 (2) 62-62, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-2. Recent Advances of Imaging for Diagnosis and Prognostication of Newly Diagnosed
Kosei Matsue
DIVISION OF HEMATOLOGU / ONCOLOGY, KAMEDA GENERAL HOSPITAL
International Journal of Myeloma 8 (2) 63-63, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-3. Management and Biology of Myeloma Bone Disease : Current Treatments and Future Targets
Hirokazu Miki
Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
International Journal of Myeloma 8 (2) 64-64, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-4. Diagnosis and treatment of neuropathy associated with plasma cell proliferatiove disorders
Sonoko Misawa
Department of Neurology, Chiba University Graduate School of Medicine
International Journal of Myeloma 8 (2) 65-65, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-1. New myeloma treatment strategies based on immune status : molecular-targeted and immune therapies
Hideto Tamura1, Mariko Ishibashi2, Hidemi Takahashi2, Koiti Inokuchi1
1Department of Hematology, Nippon Medical School, 2Department of Microbiology and Immunology, Nippon Medical School
International Journal of Myeloma 8 (2) 66-66, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-2. Dual actions of HDAC inhibitors for myeloma therapy-cell signaling block and enhanced tumor immunity
Yoichi Imai1, Mitsuhito Hirano2, Kota Sato2, Muneyoshi Futami2, Arinobu Tojo1,2
1Department of Hematology / Oncology, The University of Tokyo, The Institute of Medical Science, IMSUT Hospital, 2Division of Molecular Therapy, The University of Tokyo, Advanced Clinical Research Center
International Journal of Myeloma 8 (2) 67-67, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-3. Clinical development of CAR-T therapy for multiple myeloma : Current Status and Challenge
Ken Ohmine
Jichi Medical University
International Journal of Myeloma 8 (2) 68-68, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-4. Development of a novel CAR T-cell therapy against multiple myeloma
Naoki Hosen
Cancer Stem Cell Biology, Osaka University Graduate School of Medicine
International Journal of Myeloma 8 (2) 69-69, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY4-1. Progress of Immunotherapy Strategies in Multiple Myeloma
Saad Z.Usmani
Levine Cancer Institute / Carolinas Healthcare System
International Journal of Myeloma 8 (2) 70-70, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY4-2. Treatment strategies for multiple myeloma in the era of novel drugs
Keith Stewart
Division of Hematology / Oncology, Mayo Clinic
International Journal of Myeloma 8 (2) 71-71, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY4-3. Treatment for transplant-eligible multiple myeloma patients - Current situations and future task in Japan -
Kazutaka Sunami
Department of Hematology, National Hospital Organization Okayama Medical Center
International Journal of Myeloma 8 (2) 72-72, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY4-4. Treatment strategy in transplant-ineligible patients with multiple myeloma
Dai Maruyama
Department of Hematology, National Cancer Center Hospital
International Journal of Myeloma 8 (2) 73-73, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY5-1. Diagnosis and treatment with novel agents of AL amyloidosis
Yutaka Okuno1, Hiroyuki Hata2, Yawara Kawano1
1Department of Hematology, Kumamoto University Graduate School of Medicine, 2Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University
International Journal of Myeloma 8 (2) 74-74, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY5-2. Current treatment strategies for primary AL amyloidosis including high-dose melphalan and autologous stem-cell transplantation
NOBUHIRO TSUKADA
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 8 (2) 75-75, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY5-3. Genetic and transcriptional landscape of plasma cells in POEMS syndrome
Naoya Mimura
Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital
International Journal of Myeloma 8 (2) 76-76, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY5-4. The efficacy of autologous stem cell transplantation in POEMS syndrome
Emiko Sakaida
Department of Hematoloy, Chiba University Hospital
International Journal of Myeloma 8 (2) 77-77, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS1-1. Development of a novel mouse model of multiple myeloma
Ola Rizq1, Naoya Mimura2,3, Tohru Iseki2,3, Emiko Sakaida3, Chiaki Nakaseko3,4, Atsushi Iwama1
1Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, Chiba University Hospital, 4Department of Hematology, School of Medicine, International University of Health and Welfare
International Journal of Myeloma 8 (2) 80-80, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS1-2. Immunostaining for CCND1, MMSET, and MAF in multiple myeloma : A useful method for detecting rearrangements involving these genes
Takayuki Murase1, Masaki Ri2, Tomoko Narita2, Takashi Yoshida2, Ayako Masaki1, Shinsuke Iida2, Hiroshi Inagaki1
1Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, 2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 8 (2) 81-81, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS1-3. Platelets enhance multiple myeloma progression via IL-1β upregulation
Shokichi Tsukamoto1,2, Satoshi Takagi2, Park Jihye2, Kelly E Johnson3, Yawara Kawano2,4, Michele Moschetta2, Chia-Jen Liu2, Yuji Mishima2, Katsutoshi Kokubun2, Salomon Manier2, Karma Z Salem2, Daisy Huynh2, Antonio Sacco2, Jodi Forward3, Aldo M Roccaro2, Chiaki Nakaseko1,5, Emiko Sakaida1, Elisabeth M Battinelli3, Irene M Ghobrial2
1Department of Hematology, Chiba University Hospital, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 3Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, 4Department of Hematology, Kumamoto University Hospital, 5Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 82-82, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS2-1. ELOTUZUMAB (ELO) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) : RANDOMIZED OPEN-LABEL PH2 JAPAN STUDY
Mitsuo Hori1, Kensuke Ohta2, Hiroshi Handa3, Gen Kinoshita4, Suresh Shelat5, Masafumi Miyoshi4, Naoki Takezako6, Kohmei Kubo7
1Department of Hematology, Ibaraki Prefectural Central Hospital, 2Osaka Saiseikai Nakatsu Hospital, 3Gunma University Hospital, 4Bristol-Myers Squibb K.K., 5Bristol-Myers Squibb, 6National Hospital Organization Disaster Medical Center, 7Aomori Prefectural Central Hospital
International Journal of Myeloma 8 (2) 83-83, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS2-2. BORTEZOMIB / MELPHALAN / PREDNISONE (VMP) +- DARATUMUMAB (D) IN NDMM : JAPANESE COHORT OF ALCYONE
Tomoaki Fujisaki1, Mateos Maria-Victoria2, Meletios A Dimopoulos3, Kenshi Suzuki4, Sung-Soo Yoon5, Christopher Chiu6, Jianping Wang7, Robin Robin8, Wendy Crist6, William9, William Deraedt9, Huong Nguyen7, Ming Qi6, Jesus San-Miguel10
1Matsuyama Red Cross Hospital, 2University Hospital of Salamanca / IBSAL, 3National and Kapodistrian University of Athens, 4Department of Hematology, Japanese Red Cross Medical Center, 5Department of Internal Medicine, Seoul National University College of Medicine, 6Janssen Research and Development, LLC, 7Janssen Research & Development, LLC, 8Janssen Biotech, 9Janssen Research & Development, LLC, 10Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC
International Journal of Myeloma 8 (2) 84-84, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS2-3. Final Results of a Phase I / II Study of Carfilzomib Monotherapy in Japanese Patients with RRMM
Kazutaka Sunami1, Takashi Watanabe2,3, Kensei Tobinai2, Morio Matsumoto4, Kenshi Suzuki5, Tadao Ishida5,6, Kiyoshi Ando7, Takaaki Chou8, Shuji Ozaki9, Masafumi Taniwaki10, Naokuni Uike11,12, Hirohiko Shibayama13, Kiyohiko Hatake14, Koji Izutsu2,15, Takayuki Ishikawa16, Shinsuke Iida17
1Department of Hematology, National Hospital Organization Okayama Medical Center, 2Department of Hematology, National Cancer Center Hospital, 3Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, 4Department of Hematology, National Hospital Organization Shibukawa Medical Center, 5Department of Hematology, Japanese Red Cross Medical Center, 6Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, 7Department of Hematology and Oncology, Tokai University School of Medicine, 8Department of Internal Medicine, Niigata Cancer Center Hospital, 9Department of Hematology, Tokushima Prefectural Central Hospital, 10Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 11Department of Hematology, National Hospital Organization Kyushu Cancer Center, 12Department of Palliative Care Medicine, Saga-Ken Medical Centre Koseikan, 13Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 14Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 15Department of Hematology, Toranomon Hospital, 16Department of Hematology, Kobe City Medical Center General Hospita, 17Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 8 (2) 85-85, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS3-1. DARATUMUMAB + BORTEZOMIB / MELPHALAN / PREDNISONE (D-VMP) VS VMP IN TRANSPLANT INELIGIBLE NDMM (ALCYONE)
Kenshi Suzuki1, Maria-Victoria Mateos2, Meletios A Dimopoulos3, Michele Cavo4, Andrzej Jakubowiak5, Stefan Knop6, Chantal Doyen7, Paulo Paulo8, Zsolt Nagy9, Polina Kaplan10, Pour Pour11, Mark Cook12, Sebastian Grosicki13, Andre Crepaldi14, Anne Liberati15, Philip Campbell16, Tatiana Shelekhova17, Sung-Soo Yoon18, Genadi Iosava19, Mamta Garg20
1Department of Hematology, Japanese Red Cross Medical Center, 2University Hospital of Salamanca / IBSAL, 3National and Kapodistrian University of Athens, 4Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 5University of Chicago Medical Center, 6Wurzburg University Medical Center, 7Universite catholique de Louvain, 8Champalimaud Centre for the Unknown, 9Semmelweis Egyetem, 10Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, 11University Hospital Brno, 12University Hospitals Birmingham NHS Trust, 13Department of Cancer Prevention, School of Public Health, Silesian Medical University in Katowice, 14Clinica de Tratamento E, 15Azienda Ospedaliera "Santa Maria", 16Andrew Love Cancer Centre, 17Clinic of Professional Pathology
International Journal of Myeloma 8 (2) 86-86, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS3-2. RD + / - DARATUMUMAB IN EAST ASIAN AND JAPANESE RRMM PATIENTS IN POLLUX : UPDATED ANALYSIS
Shinsuke Iida1, Meletios A Dimopoulos2, Naoki Takezako3, Shinichiro Okamoto4, Atsushi Shinagawa5, Morio Matsumoto6, Hiroshi Kosugi7, Sung-Soo Sung-Soo8, Shang-Yi Huang9, Xiang Qin10, Ming Qi10, Kenshi Suzuki11
1Nagoya City University Graduate School of Medical Sciences, 2National and Kapodistrian University of Athens, 3Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 4Keio University Hospital, 5Hitachi General Hospital, 6Department of Hematology, National Hospital Organization Shibukawa Medical Center, 7Department of Hematology, Ogaki Municipal Hospital, 8Department of Internal Medicine, Seoul National University Hospital, 9National Taiwan University Hospital, 10Janssen Research & Development, LLC, 11Japanese Red Cross Medical Center, Department of Hematology
International Journal of Myeloma 8 (2) 87-87, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS3-3. The clinical outcomes of lenalidomide and dexamethasone in patients with relapsed / refractory multiple myeloma
Ho Sup Lee1, Chang-Ki Min2, Kihyun Kim3, Je-Jung Lee4, Sung-Soo Yoon5, Hyo Jung Kim6, Jin Seok Kim7, Hyeon-Seok Hyeon-Seok8, Sung-Hyun Kim9, Seong Kyu Park10
1Department of Internal Medicine, Kosin University College of Medicine, 2Department of Internal Medicine, Seoul St.Mary's Hospital, Catholic University of Korea, 3Department of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, 4Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 5Department of Internal Medicine, Seoul National University Hospital, 6Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 7Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 8Department of Internal Medicine, National Cancer Center of Korea, 9Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, 10Department of Hematology / Oncology, Soonchunhyang University Bucheon Hospital
International Journal of Myeloma 8 (2) 88-88, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS3-4. PHASE 1A / AB DOSE-FINDING STUDY OF CWP291 IN MYELOMA WITH OR WITHOUT LENALIDOMIDE AND DEXAMETHASONE
Sung-Soo Yoon1, Elisabet Manasanch2, Chang-Ki Min3, Jin Seok Kim4, Kenneth H.Shain5, Robert S Hauptschein6, Jeongeun Choi7, Kyoung-June Kyoung-June7
1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 2The University of Texas MD Anderson Cancer Center, 3The Catholic University of Korea, Seoul St.Mary's Hospital, 4Yonsei University College of Medicine, Severance Hospital, 5Moffitt Cancer Center, 6JW Theriac Pharmaceutical, 7JW Pharmaceutical Corporation
International Journal of Myeloma 8 (2) 89-89, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS4-1. IMMUNOLOGIC CHARACTERIZATION OF TUMOR ANTIGEN-SPECIFIC T CELL IN MULTIPLE MYELOMA
Yoon Seok Choi1, Minsuk Kwon2, Eui-Cheol Shin2, Deog-Yeon Jo1
1Department of Internal Medicine, Chungnam National University College of Medicine, 2Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST
International Journal of Myeloma 8 (2) 90-90, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS4-2. Immunomodulatory drug prevents the infection-triggered progression via down-regulation of Toll-like receptor CD180.
Jiro Kikuchi1, Yoshiaki Kuroda1, Daisuke Koyama1, Naoki Osada1, Tohru Izumi2, Hiroshi Yasui3, Takakazu Kawase4, Tatsuo Ichinohe4, Yusuke Furukawa1
1Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 2Division of Hematology, Tochigi Cancer Center, 3The Institute of Medical Science, The University of Tokyo, 4Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.
International Journal of Myeloma 8 (2) 91-91, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS4-3. Activated glycolytic genes are possible therapeutic targets against myeloma cells in hypoxic microenvironment.
Sho Ikeda1, Akihiro Kitadate1,2, Fumito Abe1, Takahiro Kobayashi1, Naoto Takahashi1, Hiroyuki Tagawa1
1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine., 2Department of Hematology and Oncology, Kameda General Hospital
International Journal of Myeloma 8 (2) 92-92, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
WS4-4. Potent anti-myeloma activity of a syringolin analog : A dual proteasome inhibitor of β2 / β5 subunits
Takashi Yoshida, Masaki Ri, Takashi Kanamori, Sho Aoki, Shiori Kinoshita, Tomoko Narita, Haruhito Totani, Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida
Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 8 (2) 93-93, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O1-1. Real-world use of ixazomib for multiple myeloma : single institution analysis on 42 cases
Nobuhiro Tsukada, Kota Sato, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 8 (2) 96-96, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O1-2. FINAL RESULTS OF PHASE I STUDY OF CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE RRMM
Takaaki Chou1, Kenshi Suzuki2, Masaki Ri3, Isamu Sugiura4, Naoki Takezako5, Kazutaka Sunami6, Tadao Ishida2,7, Tohru Izumi8, Shuji Ozaki9, Shinsuke Iida3
1Dpt.Internal Medicine, Niigata Cancer Center Hospital, 2Department of Hematology, Japanese Red Cross Medical Center, 3Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Science, 4Department of Hematology and Oncology, Toyohashi Municipal Hospital, 5Department of Hematology, National Hospital Organization Disaster Medical Center, 6Department of Hematology, National Hospital Organization Okayama Medical Center, 7Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, 8Department of Hematology, Tochigi Cancer Center, 9Department of Hematology, Tokushima Prefectural Central Hospita
International Journal of Myeloma 8 (2) 97-97, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O1-3. The results of KRd and IRd therapy for relapsed and / or refractory multiple myeloma in our hospital.
Shin-ichi Fuchida1, Yoko Kado2, Fumiaki Kitazawa2, Yoko Taminishi-katsuragawa1, Akira Okano1, Mayumi Hatsuse1, Satoshi Murakami1, Chihiro Shimazaki1
1Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, 2Department of Pharmacy, JCHO Kyoto Kuramaguchi Medical Center
International Journal of Myeloma 8 (2) 98-98, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O1-4. LONG-TERM SAFETY & EFFICACY OF ELOTUZUMAB IN RELAPSED / REFRACTORY MULTIPLE MYELOMA : JAPAN PH1 STUDY
Hirokazu Nagai1, Takaaki Chou2, Gen Kinoshita3, Masafumi Miyoshi3, Shinsuke Iida4
1Department of Hematology, National Hospital Organization Nagoya Medical Center, 2Niigata Cancer Center Hospital, 3Bristol-Myers Squibb K.K., 4Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 8 (2) 99-99, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O1-5. Elotuzumab, Lenalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Kanji Miyazaki, Takao Yogo, Kota Sato, Yu Abe, Yumiko Yoshiki, Kiyoshi Okazuka, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 8 (2) 100-100, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O2-1. Clinical Features and Risk Factors for Progression in Korean Patients with Smoldering Myeloma (KMM-172)
Byung-Su Kim1, Kihyun Kim2, Chang-Ki Min3, Chul-Won Suh4, Jin Seok Kim5, Jae Hoon O Lee6, Soo-Mee Bang7, Je-Jung Lee8, Ho-Young Yhim9, Ho-Jin Shin10, Lee Ho Sup11, Yoo Jin Lee12, Hyeon-Seok Eom13, Young Rok Do14, Hyo Jung Kim15, Sung Hyun Kim16, Seung-Hyun Nam17, Sung-Yong Kim18, Yong Park19, Jae-Cheol Jo20
1Department of Hemato-Oncology, Hallym University Dongtan Sacred Heart Hospital, 2Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 3Department of Internal Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, 4Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 5Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, 6Department of Internal Medicine, Gachon University Gil Hospital, 7Department of Internal Medicine, Seoul National University Bundang Hospital, 8Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 9Chonbuk National University Medical School, 10Pusan National University Hospital, 11Kosin University Gospel Hospital, 12Department of Internal Medicine, Kyungpook National University Hospital, 13Hematology-Oncology Clinic, National Cancer Center, 14Division of Hematology-Oncology, Department of Medicine, Dongsan Medical Center, Keimyung University School of Medicine, 15Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 16Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, 17VHS Medical Center
International Journal of Myeloma 8 (2) 101-101, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O2-2. Detection of MYD88 L265P mutation by next-generation sequencing in peripheral blood mononuclear cells of Waldenstrom's macroglobulinemia and IgM MGUS
Chikako Ohwada1, Ayako Nakamura3, Masahiro Takeuchi1, Yusuke Takeda1, Shokichi Tsukamoto1, Naoya Mimura2, Nagisa Oshima1, Yasumasa Sugita9, Hiroaki Tanaka8, Hisashi Wakita3, Nobuyuki Aotsuka3, Kosei Matsue7, Osamu Ohara5,6, Chiaki Nakaseko1,4, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Hematology and Oncology, Japanese Red Cross Narita Hospital, 4Department of Hematology, International University of Health and Welfare School of Medicine, 5Future Medicine Education and Research Organization, Chiba University, 6Department of Technology Development, Kazusa DNA Research Institute, 7Department of Hematology / Oncology, Kameda General Hospital, 8Department of Hematology, Asahi General Hospital, 9Department of Hematology, Oami Municipal Hospital
International Journal of Myeloma 8 (2) 102-102, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O2-3. Prevalance of translocation t (11 ; 14) in patients with AL amyloidosis and concomitant multiple myeloma
Hiroki Kobayashi, Yoshiaki Abe, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
Department of Hematology and Oncology, Kameda Medical Center
International Journal of Myeloma 8 (2) 103-103, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O2-4. The efficacy of bortezomib for systemic AL amyloidosis : A retrospective multicenter study in Chiba
Yusuke Takeda1, Shokichi Tsukamoto1, Naoya Mimura1,2, Masahiro Takeuchi1, Chikako Ohwada1, Hiroki Kobayashi3, Kentaro Narita3, Kosei Matsue3, Ryoh Shimizu4, Hiroaki Tanaka4, Nobuyuki Aotsuka5, Yasumasa Sugita6, Takeaki Sugawara7, Masahiro Onoda8, Shinichi Ozawa9, Satoru Hara10, Ryuko Cho11, Yasuhiro Matsuura12, Chiaki Nakaseko1,13, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Divison of Hematology / Oncology, Kameda Medical Center, 4Department of Hematology, Asahi General Hospital, 5Department of Hematological Oncology, Japanese Red Cross Narita Hospital, 6Department of Hematology, Oami Municipal Hospital, 7Department of Hematology-Oncology, Chiba Cancer Center, 8Department of Hematology, Chiba Aoba municipal Hospital, 9Department of Internal medicine, JCHO Funabashi Central Hospital, 10Department of Hematological Oncology, Chiba Rosai Hospital, 11Department of Hematology, Chibaken Saiseikai Narashino Hospital, 12Department of Hematology, Inoue Memorial Hospital, 13Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 104-104, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O2-5. Clinical outocomes of plasma cell leukemia : a single institution's experience
Shinichiro Matsui, Nobuyuki Aotsuka, Yuri Kawashima, Jun Takiguchi, Ayako Nakamura, Hironori Arai, Yoshikazu Utsu, Hiromi Yuasa, Shinichi Masuda, Hisashi Wakita
Department of Hematology Oncology, Japanese Red Cross Narita Hospital
International Journal of Myeloma 8 (2) 105-105, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O3-1. HDAC1 / 3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death
Takeshi Harada1, Asuka Oda2, Jumpei Teramachi3, Ariunzaya Bat-Erdene2, Masami Iwasa2, Yusaku Maeda1, Shingen Nakamura2, Masahiro Oura1, Shiro Fujii2, Hirokazu Miki4, Kumiko Kagawa2, Teru Hideshima5, Kenneth C.Anderson5, Masahiro Abe2
1Department of Hematology, Tokushima University Hospital, 2Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3Department of Tissue Regeneration, Tokushima University Graduate School, 4Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 5Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
International Journal of Myeloma 8 (2) 106-106, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O3-2. Amplification of the IFN-γ-STAT1- PD-L1 pathway in myeloma cells by panobinostat
Masami Iwasa1, Takeshi Harada1, Ariunzaya Bat-Erdene1, Asuka Oda1, Yusaku Maeda1, Mamiko Takahashi1, Masahiro Ooura1, Junpei Teramachi2, Shiro Fujii1, Shingen Nakamura1, Hirokazu Miki3, Kumiko Kagawa1, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Tokushima University, 2Department of Tissue Regeneration, Tokushima University, 3Division of Transfusion Medicine and Cell therapy, Tokushima University
International Journal of Myeloma 8 (2) 107-107, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O3-3. Upregulation of PD-L1 on myeloma cells by immunomodulatory agents enhances the effect of durvalumab
Mariko Ishibashi1, Hideto Tamura2
1Department of Microbiology and Immunology, Nippon Medical School, 2Division of Hematology, Department of Medicine, Nippon Medical School
International Journal of Myeloma 8 (2) 108-108, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O3-4. Elucidation of IMiDs-resistant mechanism and induction of CRBN-independent myeloma cell death.
Ryo Uozaki1, Takumi Hutou1, Hiroki Tuzi1, Kouichi Samata1, shuji Aida1, Misa Nakamura1, Hirosi Yanagawa1,2, Daijyu Ichikawa1, Maiko Matusita1, Yutaka Hattori1
1Keio University Faculty of Pharmacy, 2IDAC Theranostics, Inc.
International Journal of Myeloma 8 (2) 109-109, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O3-5. Dual targeting of cell cycle checkpoint and histone deacetylase overcomes bortezomib resistance in multiple myeloma
Takayuki Tabayashi, Yuka Tanaka, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Morihiko Sagawa, Tomoe Anan, Reiko Nakaseko, Michihide Tokuhira, Masahiro Kizaki
Department of Hematology, Saitama Medical Center, Saitama Medical University
International Journal of Myeloma 8 (2) 110-110, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O4-1. Pomalidomide + Low-Dose Dexamethasone in Relapsed and / or Refractory Multiple Myeloma (RRMM)
Anjan Thakurta12, Nizar J Bahlis1, Gary J Schiller2, Kevin Song3, Richy Agajanian4, Keith Stockerl-Goldstein5, Hakan Kaya6, Michael Sebag7, Christy Samaras8, Eshan Malek9, Giampaolo Talamo10, Christopher S Seet11, Jorge Mouro12, Faizar Zafar12, Weiyuan Chung12, Shankar Srinivasan12, Max Qian12, Amit Agawal12, David S Siegel13
1University of Calgary, 2David Geffen School of Medicine at UCLA, 3Vancouver General Hospital, 4The Oncology Institute of Hope and Innovation, 5Washington University School of Medicine, 6Cancer Care Northwest, 7McGill University Health Centre, 8Cleveland Clinic, 9University Hospitals Case Medical Center, 10Penn State Hershey Cancer Institute, 11UCLA Medical Center, 12Celgene Corporation, 13John Theurer Cancer Center, Hackensack University Medical Center
International Journal of Myeloma 8 (2) 111-111, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O4-2. The safety and efficacy of pomalidomide in combination with cyclophosphamide and dexamethasone (PCD)
Ho Sup Lee1, Chang-Ki Min2, Kihyun Kim3, Je-Jung Lee4, Sung-Soo Yoon5, Jin Seok Kim6, Hyeon-Seok Eom7, Won Sik Won Sik8, Ho-Jin Shin9, Young Rok Do10
1Department of Internal Medicine, Kosin University College of Medicine, 2Department of Internal Medicine, Seoul St.Mary's Hospital, Catholic University of Korea, 3Department of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, 4Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 5Department of Internal Medicine, Seoul National University Hospital, 6Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 7Department of Internal Medicine, National Cancer Center of Korea, 8Department of Internal Medicine, Busan Paik Hospital, 9Department of Internal Medicine, Pusan National University Hospital, 10Department of Hemato-Oncology, Keimyung University Dongsan Medical Center
International Journal of Myeloma 8 (2) 112-112, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O4-3. THALIDOMIDE-CONTAINING REGIMENS IN RELAPSED / REFRACTORY MULTIPLE MYELOMA AFTER BORTEZOMIB AND LENALIDOMIDE
Hyo Jung Kim4, Do Young Kim1, Ki Sun Jung2, Kihyun Kim3, Sung hyun Kim5, Jeong-Ok Lee6, Jin Seok Kim7, Je-Jung Lee8, Hyeon-Seok Eom9, Ho-Jin Shin1
1Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, 2Division of Hematology-Oncology, Departments of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, 3Division of Hematology-Oncology, Departments of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 4Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 5Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, 6Department of Internal Medicine, Seoul National University Bundang Hospital, 7Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 8Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 9Hematology-Oncology Clinic, National Cancer Center
International Journal of Myeloma 8 (2) 113-113, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O4-4. Response-guided MPB / Rd sequential therapy for newly diagnosed transplant-ineligible MM
Reiko Isa1, Nobuhiko Uoshima2, Ryoichi Takahashi3, Eri Kawata2, Hiroto Kaneko4, Kazuho Shimura4, Yuri Kamitsuji5, Tomoko Shimomura1, Shinsuke Mizutani1, Yoshiaki Chinen1, Muneo Oshiro6, Takahiro Fujino1, Yuka Kawaji1, Hitoji Uchiyama6, Sonoko Akamatsu3, Nana Sasaki2, tsutomu Kobayashi1, Masafumi Taniwaki4, Junya Kuroda1
1Division of Hematology, Kyoto Prefectural University of Medicine, 2Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, 3Department of Hematology, Omihachiman Community Medical Center, 4Department of Internal Medicine, Aiseikai Yamashina Hospital, 5Department of Hematology, Fukuchiyama City Hospital, 6Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital
International Journal of Myeloma 8 (2) 114-114, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O4-5. Weekly Bortezomib / Dexamethasone plus melphalan induction for untreated transplant ineligible multiple myeloma
Hideki Asaoku1, Mitsuhiro Itagaki1, Yuta Katayama1, Takeshi Okatani1, Ryouta Imanaka1, Kouhei Kyo1, Tatsuji Mino1, Shinya Katsutani2, Kouji Iwato3
1Dept Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 2Dept Clinical Laboratory, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 3Dept Blood Transhusion, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
International Journal of Myeloma 8 (2) 115-115, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O5-1. Retrospective analysis of peripheral blood stem cell harvest for plasma cell neoplasm patients in our institution
Daisuke Kudo, Risen Hirai, Akira Tanimura, Masataka Takeshita, Akiyoshi Miwa
Department of hematology, Tokyo-kita Medical Center
International Journal of Myeloma 8 (2) 116-116, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O5-2. Predictive factors for poor mobilizer of peripheral blood stem cells in multiple myeloma
Tsuyoshi Sato1, Ryutaro Shimada1, Motoki Takano2, Shigeki Ito3
1Fifth grade, Iwate Medical University School of Medicine, 2Department of Hematology, Hachinohe Red-cross Hospital, 3Department of Clinical Oncology, Iwate Medical University School of Medicine
International Journal of Myeloma 8 (2) 117-117, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O5-3. Retrospective study of reduced-dose melphalan in auto-PBSCT for elderly multiple myeloma patients
Yuri Tamura, Akira Yokota, Arata Ishii, Katsuhiro Shono, Masahiro Onoda
Chiba Aoba Municipal Hospital
International Journal of Myeloma 8 (2) 118-118, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O5-4. A comparison of Bd versus CyBorD versus VRD in newly diagnosed multiple myeloma who are candidates for autologous stem cell transplantation
Momoko Nakamura, Satoshi Yoshioka, Madoka Kato, Takuto Mori, Atsushi Tanaka, Mari Morita, Tomohiro Yabushita, Ayumi Fujimoto, Yoshimitsu Shimomura, Yuichiro Ono, Nobuhiro Hiramoto, Noboru Yonetani, Akiko Matsushita, Takayuki Ishikawa
Kobe City Medical Center General Hospital
International Journal of Myeloma 8 (2) 119-119, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O5-5. Outcomes of autologous stem cell transplantation versus chemotherapy alone in patients with AL amyloidosis
Kanji Miyazaki, Takao Yogo, Kota Sato, Yu Abe, Yumiko Yoshiki, Kiyoshi Okazuka, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 8 (2) 120-120, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O6-1. Analysis of CD38 expression and changes in lymphocyte subsets during daratumumab treatment
Akihiro Kitadate, Hiroki Kobayashi, Yoshiaki Abe, Kentaro Narita, Masami Takeuchi, Kosei Matsue
Department of Internal Medicine, Division of Hematology / Oncology, Kameda Medical Center
International Journal of Myeloma 8 (2) 121-121, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O6-2. Flow-cytometric quantification of minimal residual disease (MRD) in myeloma; a comparison of 8-color 2 tube methods with Dura Clone and Euro-Flow
Kentaro Narita1, Takeshi Yoroidaka2, Momoko Fujisawa2, Hiroyuki Takamatsu1, Shinji Nakao2, Kosei Matsue1
1Division of Hematology / Oncology, Department of Medicine, Kameda Medical Center, 2Haematology / Respiratory Medicine, Kanazawa Univiersity
International Journal of Myeloma 8 (2) 122-122, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O6-3. Assessment of bone marrow myeloma cells utilizing OneFlow(TM) PCST / PCD tube.
Risen Hirai1, Akira Tanimura1, Daisuke Kudo1, Masataka Takeshita1, Shin Sano2, Masaru Ueno2, Akiyoshi Miwa1
1Department of Hematology, Tokyo-Kita Medical Center, 2Clinical Laboratory, Tokyo-Kita Medical center
International Journal of Myeloma 8 (2) 123-123, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O6-4. Clinical significance of metabolic and volumetric parameters of FDG-PET / CT in multiple myeloma
Toshio Asayama1, Hideto Tamura1, Mariko Ishibashi2, Ryosuke Kinoshita1, Yoshimitsu Fukushima3, Teruhiko Hamana3, Shinichiro Kumita3, Keiichi Moriya1, Koiti Inokuchi1
1Department of hematology, Nippon Medical School, 2Department of Microbiology and Immunology, Nippon Medical School, 3Department of radiology, Nippon Medical School
International Journal of Myeloma 8 (2) 124-124, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O6-5. Assessment of two different quantification methods of M protein in patients with multiple myeloma.
Masahiro Takeuchi1, Shintaro Izumi1, Yurie Nagai1, Tatsuzo Mishina1, Miki Yamazaki1, Yusuke Isshiki1, Kensuke Kayamori1, Kenji Kimura1, Koji Takaishi1, Yutaro Hino1, Nagisa Oshima1, Shokichi Tsukamoto1, Shio Mitsukawa2, Yusuke Takeda1, Naoya Mimura2, Chikako Ohwada1, Tohru Iseki2, Chiaki Nakaseko1,3, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 125-125, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O7-1. Significance of altered CCR10 expression in multiple myeloma cells
Yawara Kawano1, Misaki Kakoki2, Yuki Inada2, Nao Nishimura1, Yutaka Okuno1, Hiroyuki Hata2, Masao Matsuoka1
1Department of Hematology, Kumamoto University Hospital, 2Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University
International Journal of Myeloma 8 (2) 126-126, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O7-2. UPREGULATION OF CD38 EXPRESSION IN MYELOMA CELLS : AN IMPACT OF IFN-α
Ariunzaya Bat-Erdene1, Takeshi Harada1, Masami Iwasa1, Asuka Oda1, Jumpei Teramachi2, Masahiro Hiasa3, Hirofumi Tenshin3, Shiro Fujii, Kumiko Kagawa1, Shingen Nakamura1, Hirokazu Miki4, Yusaku Maeda1, Mamiko Takahashi1, Masahiro Oura1, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School of Medicine, 2Department of Tissue Regeneration, Tokushima University Graduate School of Oral Sciences, 3Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Oral Sciences, 4Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
International Journal of Myeloma 8 (2) 127-127, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O7-3. Involvement of specific genomic alterations in lenalidomide-resistance of multiple myeloma cells
Akinobu Ota1, Ichiro Hanamura2, Sivasundaram Karnan1, Akiyoshi Takami2, Yoshitaka Hosokawa1
1Department of Biochemistry, Aichi Medical University School of Medicine, 2Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine
International Journal of Myeloma 8 (2) 128-128, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O7-4. ESR MEASURED USING MICROHEMAGGLUTINATION IS NOT ELEVATED IN MONOCLONAL GAMMOPATHY COMPARED TO OTHER DISEASES
Miyoung Kim1, Hyo Jung Kim2, Eun Jin Lee1, Hee Jung Kang1, Han-Sung Kim1, Young Kyung Lee1
1Department of Laboratory Medicine, College of Medicine, Hallym University, 2Department of Internal Medicine, College of Medicine, Hallym University
International Journal of Myeloma 8 (2) 129-129, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O8-1. Safety of carfilzomib (CFZ) therapy : the Fukuoka BMT group observation of 48 RRMM patients (Pts)
Tomohiko Kamimura1,2, Tsuyoshi Muta2,3, Koichi Osaki2,4, Shuro Yoshida2,5, Ryosuke Ogawa2,3, Hiromi Iwasaki2,6, Tetsuya Eto2,5, Koji Nagafuji2,4, Toshihiro Miyamoto2,7, Koichi Akashi2,7
1Department of Hematology, Harasanshin Hospital, 2Fukuoka Blood and Marrow Transplantation Group, 3Department of Hematology / Oncology, Japan Community Healthcare Organization Kyushu Hospital, 4Division of Hematology / Oncology, Department of Internal Medicine, Kurume University Hospital, 5Department of Hematology, Hamanomachi Hospital, 6Department of Hematology, National Hospital Organization Kyusyu Medical Center, 7Department of Hematology, Oncology & Cardiovascular medicine・Kyushu University Hospital
International Journal of Myeloma 8 (2) 130-130, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O8-2. High serum ALP levels correlate with denosumab-associated hypocalcemia in myeloma patients with a bone disease
Hirokazu Miki1, Shingen Nakamura2, Masahiro Oura2, Yusaku Maeda2, Mamiko Takahashi2, Masami Iwasa2, Takeshi Harada2, Shiro Fujii2, Kumiko Kagawa2, Itsuro Endo2, Kenichi Aihara3, Masahiro Abe2
1Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 2Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3Department of Community Medicine for Diabetes and Metabolic Disorders, Tokushima University Graduate School of Biomedical Sciences
International Journal of Myeloma 8 (2) 131-131, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O8-3. Analysis of risk factors for lenalidomide-related skin rash in patients with multiple myeloma
Tomiyuki Sugi1, Yasuo Nishigami1, Hirohisa Saigo1, Homare Hanai1, Keisuke Takabatake1, Kaori Nakamura2, Morihiro Inoue3, Hua Jian3, Masao Hagihara3
1Department of Pharmacy, Eiju General Hospital, 2Department of Nursing, Eiju General Hospital, 3Department of Hematology, Eiju General Hospital
International Journal of Myeloma 8 (2) 132-132, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
O8-4. Serious adverse events during chemotherapy for myeloma : Review of the reporting system database
Hideki Tsujimura1,2, Sachiko Kamagata2, Kayo Sekine2, Toshiko Miyaki2, Akiyasu Sato1, Satoshi Maruyama1, Keiko Ono1, Takeaki Sugawara1, Mikiko Ise1, Kyoya Kumagai1,2
1Chiba Cancer Center, Division of Hematology-Oncology, 2Expert Panel for Cancer Chemotherapy
International Journal of Myeloma 8 (2) 133-133, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-1. Prognostic evaluation of surface antigen and soluble factors in multiple myeloma : KT-MM analysis
Ryosuke Kinoshita1, Mariko Ishibashi1, Hiroshi Handa2, Makoto Sasaki3, Yoichi Imai4, Norina Tanaka5, Sakae Tonosaki6, Shigeki Ito7, Atsushi Isoda8, Toshio Asayama1, Koiti Inokuchi1, Norio Komatsu3, Junji Tanaka5, Morio Matsumoto8, Michiaki Koike9, Hideto Tamura1
1Division of Hematology, Department of Medicine, Nippon Medical School, 2Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 3Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 4Department of Hematology / Oncology, the Institute of Medical Science, the University of Tokyo, 5Department of Hematology, Tokyo Women's Medical University, 6Department of Hematology, Fraternity Memorial Hospital, 7Department of Medical Oncology, Iwate Medical University School of Medicine, 8Department of Hematology, National Hospital Organization Shibukawa Medical Center, 9Department of Hematology, Juntendo University Shizuoka Hospital
International Journal of Myeloma 8 (2) 136-136, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-2. PD-1, PD-L1 and CTLA-4 gene polymorphisms associated with the susceptibility to and the clinical features of multiple myeloma.
Tetsuhiro Kasamatsu1, Maaya Awata1, Yukihiro Kanai1, Keisuke Murata1, Nanami Gotoh1, Morio Matsumoto2, Morio Sawamura2, Makiko Takizawa3, Akihiko Yokohama4, Hiroshi Handa3, Norifumi Tsukamoto5, Takayuki Saitoh1, Hirokazu Murakami1
1Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 2National Hospital Organization, Shibukawa Medical Center, 3Department of Haematology, Gunma University Graduate School of Medicine, 4Blood Transfusion Service, Gunma University Hospital, 5Oncology Centre, Gunma University Hospital
International Journal of Myeloma 8 (2) 137-137, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-3. The establishment of nationwide databank for measurement of minimal residual disease utilizing NGS.
Masataka Takeshita1,2, Risen Hirai1, Akira Tanimura2, Daisuke Kudo2, Akiyoshi Miwa1,2
1Internatinal Myeloma Center for Advanced Research and Treatment, 2Department of Hematology, Tokyo-Kita Medical Center
International Journal of Myeloma 8 (2) 138-138, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-4. Elevated eosinophil level predicts long time to next treatment in RRMM treated with lenalidomide
Kazuhito Suzuki1,2, Kaichi Nishiwaki1,2, Mitsuji Katori1,2, Tadahiro Gunji1,2, Hideki Uryu1,2, Hidekazu Masuoka1,2, Shingo Yano2
1Division of Clinical Oncology / Hematology, Jikei Kashiwa Hospital, 2Division of Clinical Oncology / Hematology, the Jikei University School of Medicine
International Journal of Myeloma 8 (2) 139-139, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-5. Fluctuation of SLAMF7 on NK cells during the treatment with Elotuzumab
Tomiteru Togano1, Shotaro Hagiwara2, kaori Tanaka-Furuyama3, Noriko Toyama-Sorimachi3
1Division of Hematology, Dept.Internal medicine, National Center for Global Health and Medicine, 2Division of Hematology Tokyo Women's Medical University, 3Department of Molecular Immunology and Inflamation, Research Institute, National Center for Global Health and Medicine
International Journal of Myeloma 8 (2) 140-140, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-1. Successful ASCT after splenectomy in multiple myeloma with hereditary spherocytosis
Rikio Suzuki1, Daisuke Furuya1, Hidetsugu Kawai1, Akifumi Ichiki3, Daisuke Ogiya1, Hiromichi Murayama2, Yoshiaki Ogawa1, Hiroshi Kawada1, Kiyoshi Ando1
1Department of Hematology / Oncology, Tokai University School of Medicine, 2Department of Hematology, Ebina General Hospital, 3Department of Hematology, Ozawa Hospital
International Journal of Myeloma 8 (2) 141-141, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-2. CLINICAL FACTORS TO PREDICT THE ENGRAFTMENT OF LOW CD34 AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Sang-A Kim1, Dong-Yeop Shin2, Youngil Kohl2, Junshik Hong2, Inho Kim2, Sung-Soo Yoon2
1Division of hematology, Department of Internal Medicine, Seoul National University Hospital, 2Division of Hematology, Department of Internal Medicine, Seoul National University Hospital
International Journal of Myeloma 8 (2) 142-142, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-3. A retrospective analysis of treatment for NDMM patients eligible for autologous hematopoietic stem cell transplantation, single center experience
Chihiro Kuwabara, Yuhei Nagao, Katsuhiro Shono, Masahiro Onoda, Akira Yokota
Department of Hematology, Chiba Aoba Municipal Hospital
International Journal of Myeloma 8 (2) 143-143, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-4. Clinical outcome and prognostic factor of autologous hematopoietic stem cell transplantation for multiple myeloma in the era of new drugs.
Saeko Ota, Yuji Shimura, Taku Tsukamoto, Yayoi Kimoto, Kazuna Tanba, Tomoko Shimomura, Yoshimi Mizuno, Mio Sugitani, Yoshiaki Chinen, Tsutomu Kobayashi, Shigeo Horiike, Junya Kuroda
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine
International Journal of Myeloma 8 (2) 144-144, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-5. Intermediate-Dose Cyclophosphamide and G-CSF for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma
Masahiro Onoda, Yuri Tamura, Arata Ishii, Yuuhei Nagao, Katuhiro Shono, Akira Yokota
Department of hematology, Chiba Aoba Municipal Hospital
International Journal of Myeloma 8 (2) 145-145, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-6. Hyper-CVAD followed by ASCT was effective for double refractory myeloma with extra medullary disease
Tadahiro Gunji, Jiro MInami, Takaki Shimada, Takeshi Saito, Atsushi Katsube, Yutaro Kamiyama, Syoko Ishii, Sayaka Oshima, Rika Hosoba, Shingo Yano
Division of Cinical Oncology and Hematology, The Jikei University School of Medicine
International Journal of Myeloma 8 (2) 146-146, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-1. Adherence support intervention for patients on ixazomib (IXZ) therapy using counseling
Noriko Yokota1,2, Nana Hasegawa3, Michiko Kawasaki1, Masami Yanagisako1, Tomohiko Kamimura2,4, Toshihiro Miyamoto2,5
1Department of Nursing, Harasanshin Hospital, 2Fukuoka Blood and Marrow Transplantation Group, 3Department of Pharmacy, Harasanshin Hospital, 4Department of Hematology, Harasanshin Hospital, 5Department of Hematology, Oncology & Cardiovascular Medicine Kyushu University Hospital
International Journal of Myeloma 8 (2) 147-147, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-2. The safety and efficacy of anti-platelets agents or anticoagulants in patients treated with immunomodulatory drugs
Koji Takaishi1, Shintaro Izumi1, Yurie Nagai1, Tatsuzo Mishina1, Miki Yamazaki1, Yusuke Isshiki1, Kensuke Kayamori1, Kenji Kimura1, Yutaro Hino1, Nagisa Oshima1, Shokichi Tsukamoto1, Shio Mitsukawa1,2, Yusuke Takeda1, Naoya Mimura1,2, Chikako Ohwada1, Masahiro Takeuchi1, Tohru Iseki1,2, Chiaki Nakaseko1,3, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 148-148, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-3. Analysis of vulnerability on survival in very elderly patients with multiple myeloma over 75 years
Kentaro Narita, Yoshiaki Abe, Hiroki Kobayshi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
Division of Hematology / Oncology, Department of Medicine, Kameda Medical Center
International Journal of Myeloma 8 (2) 149-149, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-4. Comprehensive management system for patients treated with daratumumab
Nanami Hasegawa1, Noriko Yokota2,3, Keiko Kubota1, Yuko Kono1, Tomohiko Kamimura3,4
1Department of Pharmacy, Harasanshin Hospital, 2Department of Nursing, Harasanshin Hospital, 3Fukuoka Blood and Marrow Transplantation Group, 4Department of Hematology, Harasanshin Hospital
International Journal of Myeloma 8 (2) 150-150, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-5. The treatment of an elderly multiple myeloma patient with mental disturbance under hospitalization
Naomi Shimizu1,2, Jyunichi Yamahatsu2
1Department of Hematology, Toho University Medical Center Sakura Hospital, 2Izumi central hospital
International Journal of Myeloma 8 (2) 151-151, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-6. Refractory multiple myeloma with the onset of Posterior Reversible Encephalopathy Syndrome (PRES) during the treatment
Mitsuhiro Itagaki, Hideki Asaoku, Yuta Katayama, Tatsuji Mino, Takesi Okatani, Ryouta Imanaka, Kohei Kyo, Shinnya Katsutani, Koji Iwato
Department of. Hematology, Hiroshima Red Cross Hospital
International Journal of Myeloma 8 (2) 152-152, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-1. Retrospective analysis of high-dose carfilzomib and dexamethasone therapy in multiple myeloma
Takuto Tachita, Masaki Ri, Haruna Fujinami, Yoshiko Oshima, Hirokazu Sasaki, Yoshiaki Marumo, Takashi Yoshida, Tomoko Narita, Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 8 (2) 153-153, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-2. CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRd) REAL WORLD EXPERIENCE : SHORT-TERM FOLLOW-UP DATA OF THE EFFICACY AND SAFETY IN RRMM PATIENTS
Sung-Hyun Kim1, Jin Seok Kim2, Yong Park3, Young Rok Do4, Jeong-Ok Lee5, Youngil Koh6, Dong-Yeop Shin6, Je-Jung Lee7, Hyeok Shim8, Ho Sup Lee9, Jin Lee Yoo10, Sung-Nam Lee11, Chang-Ki Min12
1Department of Internal Medicine, Dong-A University College of Medicine, 2Department of Hematology, Yonsei University College of Medicine, 3Department of Internal Medicine, Korea University School of Medicine, 4Department of Internal Medicine, Keimyung University School of Medicine, 5Department of Internal Medicine, Seoul National University Bundang Hospital, 6Department of Internal Medicine, Seoul National University Hospital, 7Department of Internal Medicine, Chonnam National University Hwasun Hospital, 8Department of Internal Medicine, Wonkwang University School of Medicine, 9Department of Internal Medicine, Kosin University Gospel Hospital, 10Department of Internal Medicine, Kyungpook National University Hospital, 11Department of Internal Medicine, Inje University Haeundae Paik Hospital, 12Department of Hematology, Seoul St.Mary's Hospital, The Catholic University of Korea
International Journal of Myeloma 8 (2) 154-154, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-3. Clinical use and outcome of Ixazomib in patients with relapsed and refractory multiple myeloma
Yasushi Hiramatsu, Yuki Goto, Kentaro Mizuhara, Naoya Mochizuki, Tomoko Inomata, Shiro Kubonishi
Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital
International Journal of Myeloma 8 (2) 155-155, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-4. Efficacy and safety of once-weekly bortezomib in relapsed / refractory multiple myeloma patients
Sang eun Yoon, Mun Yeung-Chul, Seong Chu-Myong, Nam Eun-mi, Kyoung-Eun Lee, Soon-Nam Lee
Department of Internal Medicine, Ewha Womans University
International Journal of Myeloma 8 (2) 156-156, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-5. Retrospective analysis of KRd therapy for patients with relapsed and refractory multiple myeloma
Hiroaki Tanaka1, Chihiro Kuwabara1, Ryo Shimizu1, Akihiro Ishii2, Toshiyuki Takagi1
1Department of Hematology, Asahi General Hospital, 2Department of Transfusion Medicine, Asahi General Hospital
International Journal of Myeloma 8 (2) 157-157, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-6. Experience of Using Carfilzomib in 3 Patients with RRMM at Our Department
Haruko Takizawa1, Yasunobu Sekiguchi1, Mutsumi Wakabayashi1, Hiroko Iizuka1, Sakura Sakajiri1, Keiji Sugimoto1, Shigeki Tomita2, Hiroshi Izumi2, Mitsuo Okubo3, Noriko Nakamura4, Tomohiro Sawada4, Norio Komatsu5, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Pathology, Juntendo University Urayasu Hospital, 3Department of Blood Transfusion, Juntendo University Urayasu Hospital, 4Clinical Laboratory, Juntendo University Urayasu Hospital, 5Department of Hematology, Juntendo University Hospital
International Journal of Myeloma 8 (2) 158-158, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-1. Myeloma plasma cell evaluation under daratumumab therapy
Morio Matsumoto, Masahiro Mihara, Yuri Miyazawa, Atsushi Isoda, Morio Sawamura
Department of hematology, National Hospital Organization Shibukawa Medical Center
International Journal of Myeloma 8 (2) 159-159, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-2. Lenalidomide and very low-dose dexamethasone in patients with relapsed / refractory multiple myeloma
Seok Jae Huh, Ji Hyun Lee, Sung Yong Oh, Suee Lee, Sung-Hyun Kim
Department of Internal Medicine, Dong-A University Hospital
International Journal of Myeloma 8 (2) 160-160, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-3. Evaluation of safety and efficacy of Daratumumab in heavily treated patients with multiple myeloma
Hiroki Kobayashi, Yoshiaki Abe, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
Department of Hematology and Oncology, Kameda Medical Center
International Journal of Myeloma 8 (2) 161-161, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-4. Single center experience of Pomalidomide plus dexamethasone in patients with refractory multiple myeloma
Lim Sung Won1, Silvia Park1, Seok Jin Kim1, Jun Ho Jang1, Won Seog Kim1, Chul Won Jung1, Hyo Jung Kim2, Kihyun Kim1
1Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine
International Journal of Myeloma 8 (2) 162-162, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-5. Experience of Using Pomalidomide (POM) in 10 Cases at Our Department
Mutsumi Wakabayashi1, Yasunobu Sekiguchi1, Haruko Takizawa1, Hiroko Iizuka1, Sakura Sakajiri1, Keiji Sugimoto1, Shigeki Tomita2, Hiroshi Izumi2, Mitsuo Okubo3, Noriko Nakamura4, Tomohiro Sawada4, Norio Komatsu5, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Pathology, Juntendo University Urayasu Hospital, 3Department of Blood Transfusion, Juntendo University Urayasu Hospital, 4Clinical Laboratory, Juntendo University Urayasu Hospital, 5Department of Hematology, Juntendo University Hospital
International Journal of Myeloma 8 (2) 163-163, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-6. IMiDs have provided long-term survival in a young myeloma patient who relapsed after tandem ASCT / allo-SCT
Kenji Kimura1, Shokichi Tsukamoto1, Tatsuzo Mishina1, Yurie Nagai1, Miki Yamazaki1, Arata Ishii1, Kensuke Kayamori1, Yusuke Isshiki1, Koji Takaishi1, Yutaro Hino1, Nagisa Hasegawa-Oshima1, Shio Mitsukawa1,2, Yusuke Takeda1, Naoya Mimura1,2, Masahiro Takeuchi1, Chikako Ohwada1, Tohru Iseki1,2, Emiko Sakaida1, Chiaki Nakaseko1,3
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 164-164, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-1. V-EPOCH treatment in a case of plasmablastic lymphoma / myeloma with del 17p
Kyoko Yoshihara1, Satoshi Yoshihara1, Ikuo Matsuda2, Shohei Matsuo3, Takehito Imado4, Masaya Okada1, Seiichi Hirota2, Yoshihiro Fujimori1
1Department of Transfusion and Cellular Medicine, Hyogo College Of Medicine, 2Department of Surgical Pathology, Hyogo College of Medicine, 3Department of Pathology, Takarazuka Municipal Hospital, 4Department of Hematology, Takarazuka Municipal Hospital
International Journal of Myeloma 8 (2) 165-165, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-2. Monoclonal gammopahty of renal significance (MGRS) associated with Fanconi syndrome
Shunsuke Ito1, Takaaki Miyake1, Kai Taketani2, Yusuke Okada1, Yasumasa Shimazaki1, Fumiyoshi Ikejiri1, Masakazu Notsu2, Kentaro Takase3, Masahiro Egawa3, Mika Yamauchi2, Ritsuro Suzuki1, Junji Suzumiya1
1Department of Oncology / Hematology, Shimane University Hospital, 2Department of Endoclinology and Metabolism, Shimane University Hospital, 3Department of Nephrology, Shimane University Hospital
International Journal of Myeloma 8 (2) 166-166, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-3. Very good partial response induced by daratumumab, lenalidomide, dexamethasone therapy in multiple myeloma patient with AL amyloidosis
Shinya Okuda, Hiroyuki Watanabe, Chiaki Takebayashi
Department of hematology and oncology, JR Tokyo general hospital
International Journal of Myeloma 8 (2) 167-167, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-4. Primary plasma cell leukemia with bortezomib based therapy : Report of four cases and review of the literature.
Yuhei Nagao, Yuri Tamura, Arata Ishii, Katsuhiro Shono, Masahiro Onoda, Akira Yokota
Department of Hematology, Chiba Aoba Municipal Hospital
International Journal of Myeloma 8 (2) 168-168, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-5. Bortezomib combined DA-EPOCH was effective in one patient with plasmablastic lymphoma (PBL).
Yukihiro Tokumine1, Megumu Inoue1, Naoko Ishida1, Masaaki Takahashi1, Hayato Kimura2
1Itami City Hospital, department of Hematology, 2Itami City Hospital, department of Pathology
International Journal of Myeloma 8 (2) 169-169, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-6. POEMS syndrome with a large osteolytic lesion as well as multiple sclerotic bone lesions
Tatsuzo Mishina1, Shokichi Tsukamoto1, Yurie Nagai1, Miki Yamazaki1, Arata Ishii1, Kensuke Kayamori1, Kenji Kimura1, Yusuke Isshiki1, Koji Takaishi1, Yutaro Hino1, Nagisa Hasegawa-Oshima1, Shio Mitsukawa1,2, Yusuke Takeda1, Naoya Mimura1,2, Masahiro Takeuchi1, Chikako Ohwada1, Tohru Iseki1,2, Miwa Akiyoshi3, Emiko Sakaida1, Chiaki Nakaseko1,4
1Department of Hematology, Chiba University Hospital, 2Department of Blood Transfusion and Cell Therapy, Chiba University Hospital, 3Department of Hematology, Tokyo-Kita Medical Center, 4Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 8 (2) 170-170, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-1. Factors associated with duration of treatment in Japanese multiple myeloma patients receiving second-line therapy
Ichiro Nakayama1, jun Gyungjin1, Izumi Mishiro2, Junpei Soeda1
1Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Co.Ltd., 2Japan Medical Affairs, Japan Pharma Business Unit, Takeda Pharmaceutical Co.Ltd.
International Journal of Myeloma 8 (2) 171-171, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-3. A case of multiple myeloma with repeating anemia caused by PRCA.
Katsuhiro Shono, Yuri Tamura, Arata Ishii, Yuhei Nagao, Masahiro Onoda, Akira Yokota
Department of Hematology, Chiba Aoba Municipal Hospital
International Journal of Myeloma 8 (2) 173-173, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-4. The effect of Carfilzomib and Ixazomib in relapsed and refractory multiple myeloma.
Hiroshi IKEDA1, Soushi Ibata2, Ayumi Tatekoshi1,2, Syouhei Kikuchi1,2, Kazuyuki Murase1,2, Kouichi Takada1,2, Satoshi Iyama1, Masayoshi Kobune1, Jyunji Kato2
1Department of hematology Sapporo Medical University, 2Department of oncology Sapporo Medical University
International Journal of Myeloma 8 (2) 174-174, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-5. Histological transformation of malignant lymphoma to plasma cell leukemia after immunochemotherapy
Yutaro Suzuki, Akira Honda, Junji Koya, Kazuhiro Toyama, Shunya Arai, Mineo Kurokawa
Department of Hematology and Oncology, The University of Tokyo Graduate School of Medicine
International Journal of Myeloma 8 (2) 175-175, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-6. A case of worsening arthralgia induced by Ixazomib for the patient with relapse / refractory multiple myeloma.
Jiro Minami, Takaki Shimada, Takeshi Saito, Hiroki Yokoyama, Atsushi Katsube, Yutaro Kamiyama, Tadahiro Gunji, Sayaka Oshima, Shoko Ishii, Rika Hosoba, Shingo Yano
Division of Clinical Oncology and Hematology, the jikei university of school of medicine
International Journal of Myeloma 8 (2) 176-176, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
MS1. Methods and clinical significance of microscopic residual disease in multiple myeloma[Machine Translation] (多発性骨髄腫における微小残存病変評価方法と臨床的意義)
Hiroyuki Takamatsu
Haematology / Respiratory Medicine, Kanazawa Univiersity
International Journal of Myeloma 8 (2) 178-178, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
MS2. The Novel Function and Target of Ikaros Transcription Factor.
Jiro Kikuchi, Yoshiaki Kuroda, Yusuke Furukawa
Division of Stem Cell Regulation Center for Molecular Medicine, Jichi Medical University
International Journal of Myeloma 8 (2) 179-179, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS1. Treatment of Multiple Myeloma in Relapse
Keith Stewart
Division of Hematology / Oncology, Mayo Clinic
International Journal of Myeloma 8 (2) 180-180, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS2. Clinical Findings on Multiple Myeloma
Naoki Takezako
Department of Hematology, National Hospital Organization Disaster Medical Center
International Journal of Myeloma 8 (2) 181-181, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS3. Biology and Treatment Strategy of Multiple Myeloma
Gareth John Morgan
Professor of Hematology Director, Myeloma Institute Deputy Director, Winthrop P.Rockefeller Cancer Institute University of Arkansas for Medical Sciences
International Journal of Myeloma 8 (2) 182-182, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS4. R / R MM Treatment Strategy to Consider from a Basic and Clinical Perspective[Machine Translation] (基礎と臨床の視点から考察するR / R MM治療戦略)
Kensuke Ohta1, Yusuke Furukawa2
1Osaka Saiseikai Nakatsu Hospital, 2Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University
International Journal of Myeloma 8 (2) 183-183, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
AS1-1. Multiple Myeloma 〜 Advances in the Elucidation of Pathology 〜
Junya Kuroda
Kyoto Prefectural University of Medicine
International Journal of Myeloma 8 (2) 184-184, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
AS1-2. Continuous Therapy for Myeloma in the Era of Novel Agents
Thierry FACON
University Hospital Hurriez
International Journal of Myeloma 8 (2) 185-185, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
AS2. Measures against infectious diseases in patients with myeloma[Machine Translation] (骨髄腫患者の感染症対策)
Yoshinobu Kanda
自治医科大学 内科学講座血液学部門 教授, 自治医科大学附属さいたま医療センター血液科 教授
International Journal of Myeloma 8 (2) 186-186, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
ES1. Recent Progress in Myeloma Therapy - Implications for Treatment Decisions
Saad Z.Usmani
Levine Cancer Institute / Carolinas Healthcare System
International Journal of Myeloma 8 (2) 187-187, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
ES2. MoA of Cereblon Targeting agents
Anjan Thakurta
Celgene Corporation
International Journal of Myeloma 8 (2) 188-188, 2018.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。